(Q34078018)

30 July 2017

1 reference

title

Antiviral therapies for herpes zoster infections. Are they economically justifiable? (English)

1 reference

30 July 2017

1 reference

Smith KJ

1

1 reference

30 July 2017

Roberts MS

series ordinal

2

1 reference

30 July 2017

publication date

1 August 2000

1 reference

30 July 2017

1 reference

30 July 2017

volume

18

1 reference

30 July 2017

issue

2

1 reference

30 July 2017

page(s)

95-104

1 reference

Shingles. Sorrows, salves, and solutions

30 July 2017

cites work

1 reference

12 December 2020

Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction

1 reference

12 December 2020

Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group

1 reference

12 December 2020

Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials

1 reference

12 December 2020

Primary care management of acute herpes zoster: systematic review of evidence from randomized controlled trials.

1 reference

12 December 2020

Inconsistencies in the "Societal Perspective" on Costs of the Panel on Cost-Effectiveness in Health and Medicine

1 reference

12 December 2020

Oral acyclovir in the treatment of herpes zoster in general practice

1 reference

12 December 2020

Acyclovir: A Decade Later

1 reference

12 December 2020

Zoster-associated chronic pain: an overview of clinical trials with acyclovir.

1 reference

12 December 2020

Comparison of valaciclovir and acyclovir for the treatment of herpes zoster in immunocompetent patients over 50 years of age: a cost-consequence model

1 reference

12 December 2020

Proposed classification of herpes zoster pain

1 reference

12 December 2020

Economic evaluation of antiviral therapy for the treatment of herpes zoster in immunocompetent adults

1 reference

12 December 2020

Recognition and treatment of shingles

1 reference

12 December 2020

Clinical economics. A guide to the economic analysis of clinical practices

1 reference

12 December 2020

Efficacy of oral acyclovir treatment of acute herpes zoster.

1 reference

12 December 2020

Guidelines for the management of shingles. report of a working group of the British Society for the Study of Infection (BSSI)

1 reference

12 December 2020

Lack of effect of acyclovir on postherpetic neuralgia

1 reference

12 December 2020

The cost of treatment for post-herpetic neuralgia in the UK

1 reference

12 December 2020

A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster

1 reference

12 December 2020

The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia. A meta-analysis

1 reference

12 December 2020

Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group

1 reference

12 December 2020

Herpes zoster: risk categories for persistent pain

1 reference

12 December 2020

Herpes zoster with postherpetic neuralgia--persisting pain and frustration

1 reference

12 December 2020

Oral acyclovir in acute herpes zoster

1 reference

12 December 2020

1 reference

12 December 2020

Population-based study of herpes zoster and its sequelae

1 reference

12 December 2020

Are current therapies useful for the prevention of postherpetic neuralgia? A critical analysis of the literature

1 reference

12 December 2020

Cost-consequence models for varicella-zoster virus infections.

1 reference

12 December 2020

Economic evaluation of famciclovir in reducing the duration of postherpetic neuralgia

1 reference

12 December 2020

Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults

1 reference

12 December 2020

Cost-benefit of oral acyclovir in the treatment of herpes zoster

1 reference

12 December 2020

Postherpetic neuralgia--pathogenesis, treatment, and prevention

1 reference

12 December 2020

Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients

1 reference

12 December 2020

Cost effectiveness of newer antiviral agents for herpes zoster: is the evidence spotty?

1 reference

12 December 2020

Oral acyclovir in herpes zoster ophthalmicus

1 reference

12 December 2020

Therapy of herpes zoster with oral acyclovir

1 reference

12 December 2020

10.2165/00019053-200018020-00001

Identifiers

DOI

1 reference

Dimensions Publication ID

30 July 2017

1045107073

0 references

1 reference